APO Research
Talk to an analyst

APO RESEARCH · REPORT

Critical Limb Ischemia Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Critical Limb Ischemia Drug Industry Research Report 2026

19 December 2025127 pages

Choose your research edition.

Industry ResearchCritical Limb Ischemia Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Critical Limb Ischemia Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Critical Limb Ischemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Critical Limb Ischemia Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Critical Limb Ischemia Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Critical Limb Ischemia Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Critical Limb Ischemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Critical Limb Ischemia Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Critical Limb Ischemia Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Critical Limb Ischemia Drug include U.S. Stem Cell Inc, TikoMed AB, Symic Biomedical Inc, ReNeuron Group Plc, Pluristem Therapeutics Inc, Pharmicell Co Ltd, Nissan Chemical Industries Ltd, Neurofx Inc and Kasiak Research Pvt Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Critical Limb Ischemia Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Critical Limb Ischemia Drug Market by Company

U.S. Stem Cell Inc

TikoMed AB

Symic Biomedical Inc

ReNeuron Group Plc

Pluristem Therapeutics Inc

Pharmicell Co Ltd

Nissan Chemical Industries Ltd

Neurofx Inc

Kasiak Research Pvt Ltd

Hemostemix Inc

Cynata Therapeutics Ltd

Caladrius Biosciences Inc

BiogenCell Ltd

Critical Limb Ischemia Drug Segment by Type

NK-104 NP

NFx-101

JVS-100

HC-016

Others

Critical Limb Ischemia Drug Segment by Application

Hospital

Home Care

ASCs

Critical Limb Ischemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Critical Limb Ischemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Critical Limb Ischemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Critical Limb Ischemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Critical Limb Ischemia Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Critical Limb Ischemia Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Critical Limb Ischemia Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Critical Limb Ischemia Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Critical Limb Ischemia Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Critical Limb Ischemia Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Critical Limb Ischemia Drug Revenue of Manufacturers (2021-2026) Table 9. Global Critical Limb Ischemia Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Critical Limb Ischemia Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Critical Limb Ischemia Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Critical Limb Ischemia Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Critical Limb Ischemia Drug, Product Type & Application Table 14. Global Critical Limb Ischemia Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Critical Limb Ischemia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. U.S. Stem Cell Inc Company Information Table 19. U.S. Stem Cell Inc Business Overview Table 20. U.S. Stem Cell Inc Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. U.S. Stem Cell Inc Critical Limb Ischemia Drug Product Portfolio Table 22. U.S. Stem Cell Inc Recent Developments Table 23. TikoMed AB Company Information Table 24. TikoMed AB Business Overview Table 25. TikoMed AB Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. TikoMed AB Critical Limb Ischemia Drug Product Portfolio Table 27. TikoMed AB Recent Developments Table 28. Symic Biomedical Inc Company Information Table 29. Symic Biomedical Inc Business Overview Table 30. Symic Biomedical Inc Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Symic Biomedical Inc Critical Limb Ischemia Drug Product Portfolio Table 32. Symic Biomedical Inc Recent Developments Table 33. ReNeuron Group Plc Company Information Table 34. ReNeuron Group Plc Business Overview Table 35. ReNeuron Group Plc Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. ReNeuron Group Plc Critical Limb Ischemia Drug Product Portfolio Table 37. ReNeuron Group Plc Recent Developments Table 38. Pluristem Therapeutics Inc Company Information Table 39. Pluristem Therapeutics Inc Business Overview Table 40. Pluristem Therapeutics Inc Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Pluristem Therapeutics Inc Critical Limb Ischemia Drug Product Portfolio Table 42. Pluristem Therapeutics Inc Recent Developments Table 43. Pharmicell Co Ltd Company Information Table 44. Pharmicell Co Ltd Business Overview Table 45. Pharmicell Co Ltd Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pharmicell Co Ltd Critical Limb Ischemia Drug Product Portfolio Table 47. Pharmicell Co Ltd Recent Developments Table 48. Nissan Chemical Industries Ltd Company Information Table 49. Nissan Chemical Industries Ltd Business Overview Table 50. Nissan Chemical Industries Ltd Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Nissan Chemical Industries Ltd Critical Limb Ischemia Drug Product Portfolio Table 52. Nissan Chemical Industries Ltd Recent Developments Table 53. Neurofx Inc Company Information Table 54. Neurofx Inc Business Overview Table 55. Neurofx Inc Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Neurofx Inc Critical Limb Ischemia Drug Product Portfolio Table 57. Neurofx Inc Recent Developments Table 58. Kasiak Research Pvt Ltd Company Information Table 59. Kasiak Research Pvt Ltd Business Overview Table 60. Kasiak Research Pvt Ltd Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Kasiak Research Pvt Ltd Critical Limb Ischemia Drug Product Portfolio Table 62. Kasiak Research Pvt Ltd Recent Developments Table 63. Hemostemix Inc Company Information Table 64. Hemostemix Inc Business Overview Table 65. Hemostemix Inc Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Hemostemix Inc Critical Limb Ischemia Drug Product Portfolio Table 67. Hemostemix Inc Recent Developments Table 68. Cynata Therapeutics Ltd Company Information Table 69. Cynata Therapeutics Ltd Business Overview Table 70. Cynata Therapeutics Ltd Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Cynata Therapeutics Ltd Critical Limb Ischemia Drug Product Portfolio Table 72. Cynata Therapeutics Ltd Recent Developments Table 73. Caladrius Biosciences Inc Company Information Table 74. Caladrius Biosciences Inc Business Overview Table 75. Caladrius Biosciences Inc Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Caladrius Biosciences Inc Critical Limb Ischemia Drug Product Portfolio Table 77. Caladrius Biosciences Inc Recent Developments Table 78. BiogenCell Ltd Company Information Table 79. BiogenCell Ltd Business Overview Table 80. BiogenCell Ltd Critical Limb Ischemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. BiogenCell Ltd Critical Limb Ischemia Drug Product Portfolio Table 82. BiogenCell Ltd Recent Developments Table 83. Global Critical Limb Ischemia Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Critical Limb Ischemia Drug Sales by Region (2021-2026) & (K Units) Table 85. Global Critical Limb Ischemia Drug Sales Market Share by Region (2021-2026) Table 86. Global Critical Limb Ischemia Drug Sales by Region (2027-2032) & (K Units) Table 87. Global Critical Limb Ischemia Drug Sales Market Share by Region (2027-2032) Table 88. Global Critical Limb Ischemia Drug Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Critical Limb Ischemia Drug Revenue Market Share by Region (2021-2026) Table 90. Global Critical Limb Ischemia Drug Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Critical Limb Ischemia Drug Revenue Market Share by Region (2027-2032) Table 92. North America Critical Limb Ischemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 94. North America Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 95. North America Critical Limb Ischemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Critical Limb Ischemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Critical Limb Ischemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 99. Europe Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 100. Europe Critical Limb Ischemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Critical Limb Ischemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Critical Limb Ischemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 104. Asia Pacific Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 105. Asia Pacific Critical Limb Ischemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Critical Limb Ischemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Critical Limb Ischemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 109. South America Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 110. South America Critical Limb Ischemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Critical Limb Ischemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Critical Limb Ischemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 114. Middle East and Africa Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 115. Middle East and Africa Critical Limb Ischemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Critical Limb Ischemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Critical Limb Ischemia Drug Sales by Type (2021-2026) & (K Units) Table 118. Global Critical Limb Ischemia Drug Sales by Type (2027-2032) & (K Units) Table 119. Global Critical Limb Ischemia Drug Sales Market Share by Type (2021-2026) Table 120. Global Critical Limb Ischemia Drug Sales Market Share by Type (2027-2032) Table 121. Global Critical Limb Ischemia Drug Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Critical Limb Ischemia Drug Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Critical Limb Ischemia Drug Revenue Market Share by Type (2021-2026) Table 124. Global Critical Limb Ischemia Drug Revenue Market Share by Type (2027-2032) Table 125. Global Critical Limb Ischemia Drug Price by Type (2021-2026) & (US$/Unit) Table 126. Global Critical Limb Ischemia Drug Price by Type (2027-2032) & (US$/Unit) Table 127. Global Critical Limb Ischemia Drug Sales by Application (2021-2026) & (K Units) Table 128. Global Critical Limb Ischemia Drug Sales by Application (2027-2032) & (K Units) Table 129. Global Critical Limb Ischemia Drug Sales Market Share by Application (2021-2026) Table 130. Global Critical Limb Ischemia Drug Sales Market Share by Application (2027-2032) Table 131. Global Critical Limb Ischemia Drug Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Critical Limb Ischemia Drug Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Critical Limb Ischemia Drug Revenue Market Share by Application (2021-2026) Table 134. Global Critical Limb Ischemia Drug Revenue Market Share by Application (2027-2032) Table 135. Global Critical Limb Ischemia Drug Price by Application (2021-2026) & (US$/Unit) Table 136. Global Critical Limb Ischemia Drug Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Critical Limb Ischemia Drug Distributors List Table 140. Critical Limb Ischemia Drug Customers List Table 141. Critical Limb Ischemia Drug Industry Trends Table 142. Critical Limb Ischemia Drug Industry Drivers Table 143. Critical Limb Ischemia Drug Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Critical Limb Ischemia Drug Product Image Figure 5. Global Critical Limb Ischemia Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Critical Limb Ischemia Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Critical Limb Ischemia Drug Sales (2021-2032) & (K Units) Figure 8. Global Critical Limb Ischemia Drug Average Price (US$/Unit) & (2021-2032) Figure 9. NK-104 NP Product Image Figure 10. NFx-101 Product Image Figure 11. JVS-100 Product Image Figure 12. HC-016 Product Image Figure 13. Others Product Image Figure 14. Hospital Product Image Figure 15. Home Care Product Image Figure 16. ASCs Product Image Figure 17. Global Critical Limb Ischemia Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Critical Limb Ischemia Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Critical Limb Ischemia Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Critical Limb Ischemia Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Critical Limb Ischemia Drug Sales by Region in 2025 Figure 23. Global Critical Limb Ischemia Drug Revenue by Region in 2025 Figure 24. North America Critical Limb Ischemia Drug Market Size by Country in 2025 Figure 25. North America Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 26. North America Critical Limb Ischemia Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Critical Limb Ischemia Drug Market Size by Country in 2025 Figure 30. Europe Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 31. Europe Critical Limb Ischemia Drug Revenue Market Share by Country (2021-2032) Figure 32. Germany Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Critical Limb Ischemia Drug Market Size by Country in 2025 Figure 38. Asia Pacific Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Critical Limb Ischemia Drug Revenue Market Share by Country (2021-2032) Figure 40. China Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Critical Limb Ischemia Drug Market Size by Country in 2025 Figure 49. South America Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 50. South America Critical Limb Ischemia Drug Revenue Market Share by Country (2021-2032) Figure 51. Mexico Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Middle East and Africa Critical Limb Ischemia Drug Market Size by Country in 2025 Figure 55. Middle East and Africa Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 56. Middle East and Africa Critical Limb Ischemia Drug Revenue Market Share by Country (2021-2032) Figure 57. Turkey Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. UAE Critical Limb Ischemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Global Critical Limb Ischemia Drug Sales Market Share by Type (2021-2032) Figure 61. Global Critical Limb Ischemia Drug Revenue Market Share by Type (2021-2032) Figure 62. Global Critical Limb Ischemia Drug Price (US$/Unit) by Type (2021-2032) Figure 63. Global Critical Limb Ischemia Drug Sales Market Share by Application (2021-2032) Figure 64. Global Critical Limb Ischemia Drug Revenue Market Share by Application (2021-2032) Figure 65. Global Critical Limb Ischemia Drug Price (US$/Unit) by Application (2021-2032) Figure 66. Critical Limb Ischemia Drug Value Chain Figure 67. Critical Limb Ischemia Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Critical Limb Ischemia Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • NK-104 NP
  • NFx-101
  • JVS-100
  • HC-016
  • Others
Applications
  • Hospital
  • Home Care
  • ASCs
Companies covered
  • U.S. Stem Cell Inc
  • TikoMed AB
  • Symic Biomedical Inc
  • ReNeuron Group Plc
  • Pluristem Therapeutics Inc
  • Pharmicell Co Ltd
  • Nissan Chemical Industries Ltd
  • Neurofx Inc
  • Kasiak Research Pvt Ltd
  • Hemostemix Inc
  • Cynata Therapeutics Ltd
  • Caladrius Biosciences Inc
  • BiogenCell Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Critical Limb Ischemia Drug Market Size (2021-2032)
  4. 2.2.2 Global Critical Limb Ischemia Drug Sales (2021-2032)
  5. 2.2.3 Global Critical Limb Ischemia Drug Market Average Price (2021-2032)
  6. 2.3 Critical Limb Ischemia Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 NK-104 NP
  9. 2.3.3 NFx-101
  10. 2.3.4 JVS-100
  11. 2.3.5 HC-016
  12. 2.3.6 Others
  13. 2.4 Critical Limb Ischemia Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital
  16. 2.4.3 Home Care
  17. 2.4.4 ASCs
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Critical Limb Ischemia Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Critical Limb Ischemia Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Critical Limb Ischemia Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Critical Limb Ischemia Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Critical Limb Ischemia Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Critical Limb Ischemia Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Critical Limb Ischemia Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Critical Limb Ischemia Drug, Established Date
  9. 3.9 Global Critical Limb Ischemia Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 U.S. Stem Cell Inc
  2. 4.1.1 U.S. Stem Cell Inc Company Information
  3. 4.1.2 U.S. Stem Cell Inc Business Overview
  4. 4.1.3 U.S. Stem Cell Inc Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 U.S. Stem Cell Inc Critical Limb Ischemia Drug Product Portfolio
  6. 4.1.5 U.S. Stem Cell Inc Recent Developments
  7. 4.2 TikoMed AB
  8. 4.2.1 TikoMed AB Company Information
  9. 4.2.2 TikoMed AB Business Overview
  10. 4.2.3 TikoMed AB Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 TikoMed AB Critical Limb Ischemia Drug Product Portfolio
  12. 4.2.5 TikoMed AB Recent Developments
  13. 4.3 Symic Biomedical Inc
  14. 4.3.1 Symic Biomedical Inc Company Information
  15. 4.3.2 Symic Biomedical Inc Business Overview
  16. 4.3.3 Symic Biomedical Inc Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Symic Biomedical Inc Critical Limb Ischemia Drug Product Portfolio
  18. 4.3.5 Symic Biomedical Inc Recent Developments
  19. 4.4 ReNeuron Group Plc
  20. 4.4.1 ReNeuron Group Plc Company Information
  21. 4.4.2 ReNeuron Group Plc Business Overview
  22. 4.4.3 ReNeuron Group Plc Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 ReNeuron Group Plc Critical Limb Ischemia Drug Product Portfolio
  24. 4.4.5 ReNeuron Group Plc Recent Developments
  25. 4.5 Pluristem Therapeutics Inc
  26. 4.5.1 Pluristem Therapeutics Inc Company Information
  27. 4.5.2 Pluristem Therapeutics Inc Business Overview
  28. 4.5.3 Pluristem Therapeutics Inc Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pluristem Therapeutics Inc Critical Limb Ischemia Drug Product Portfolio
  30. 4.5.5 Pluristem Therapeutics Inc Recent Developments
  31. 4.6 Pharmicell Co Ltd
  32. 4.6.1 Pharmicell Co Ltd Company Information
  33. 4.6.2 Pharmicell Co Ltd Business Overview
  34. 4.6.3 Pharmicell Co Ltd Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pharmicell Co Ltd Critical Limb Ischemia Drug Product Portfolio
  36. 4.6.5 Pharmicell Co Ltd Recent Developments
  37. 4.7 Nissan Chemical Industries Ltd
  38. 4.7.1 Nissan Chemical Industries Ltd Company Information
  39. 4.7.2 Nissan Chemical Industries Ltd Business Overview
  40. 4.7.3 Nissan Chemical Industries Ltd Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Nissan Chemical Industries Ltd Critical Limb Ischemia Drug Product Portfolio
  42. 4.7.5 Nissan Chemical Industries Ltd Recent Developments
  43. 4.8 Neurofx Inc
  44. 4.8.1 Neurofx Inc Company Information
  45. 4.8.2 Neurofx Inc Business Overview
  46. 4.8.3 Neurofx Inc Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Neurofx Inc Critical Limb Ischemia Drug Product Portfolio
  48. 4.8.5 Neurofx Inc Recent Developments
  49. 4.9 Kasiak Research Pvt Ltd
  50. 4.9.1 Kasiak Research Pvt Ltd Company Information
  51. 4.9.2 Kasiak Research Pvt Ltd Business Overview
  52. 4.9.3 Kasiak Research Pvt Ltd Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Kasiak Research Pvt Ltd Critical Limb Ischemia Drug Product Portfolio
  54. 4.9.5 Kasiak Research Pvt Ltd Recent Developments
  55. 4.10 Hemostemix Inc
  56. 4.10.1 Hemostemix Inc Company Information
  57. 4.10.2 Hemostemix Inc Business Overview
  58. 4.10.3 Hemostemix Inc Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Hemostemix Inc Critical Limb Ischemia Drug Product Portfolio
  60. 4.10.5 Hemostemix Inc Recent Developments
  61. 4.11 Cynata Therapeutics Ltd
  62. 4.11.1 Cynata Therapeutics Ltd Company Information
  63. 4.11.2 Cynata Therapeutics Ltd Business Overview
  64. 4.11.3 Cynata Therapeutics Ltd Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Cynata Therapeutics Ltd Critical Limb Ischemia Drug Product Portfolio
  66. 4.11.5 Cynata Therapeutics Ltd Recent Developments
  67. 4.12 Caladrius Biosciences Inc
  68. 4.12.1 Caladrius Biosciences Inc Company Information
  69. 4.12.2 Caladrius Biosciences Inc Business Overview
  70. 4.12.3 Caladrius Biosciences Inc Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Caladrius Biosciences Inc Critical Limb Ischemia Drug Product Portfolio
  72. 4.12.5 Caladrius Biosciences Inc Recent Developments
  73. 4.13 BiogenCell Ltd
  74. 4.13.1 BiogenCell Ltd Company Information
  75. 4.13.2 BiogenCell Ltd Business Overview
  76. 4.13.3 BiogenCell Ltd Critical Limb Ischemia Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 BiogenCell Ltd Critical Limb Ischemia Drug Product Portfolio
  78. 4.13.5 BiogenCell Ltd Recent Developments
5 Global Critical Limb Ischemia Drug Market Scenario by Region
  1. 5.1 Global Critical Limb Ischemia Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Critical Limb Ischemia Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Critical Limb Ischemia Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Critical Limb Ischemia Drug Sales by Region: 2027-2032
  5. 5.3 Global Critical Limb Ischemia Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Critical Limb Ischemia Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Critical Limb Ischemia Drug Revenue by Region: 2027-2032
  8. 5.4 North America Critical Limb Ischemia Drug Market Facts & Figures by Country
  9. 5.4.1 North America Critical Limb Ischemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Critical Limb Ischemia Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Critical Limb Ischemia Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Critical Limb Ischemia Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Critical Limb Ischemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Critical Limb Ischemia Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Critical Limb Ischemia Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Critical Limb Ischemia Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Critical Limb Ischemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Critical Limb Ischemia Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Critical Limb Ischemia Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Critical Limb Ischemia Drug Market Facts & Figures by Country
  35. 5.7.1 South America Critical Limb Ischemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Critical Limb Ischemia Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Critical Limb Ischemia Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Critical Limb Ischemia Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Critical Limb Ischemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Critical Limb Ischemia Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Critical Limb Ischemia Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Critical Limb Ischemia Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Critical Limb Ischemia Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Critical Limb Ischemia Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Critical Limb Ischemia Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Critical Limb Ischemia Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Critical Limb Ischemia Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Critical Limb Ischemia Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Critical Limb Ischemia Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Critical Limb Ischemia Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Critical Limb Ischemia Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Critical Limb Ischemia Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Critical Limb Ischemia Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Critical Limb Ischemia Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Critical Limb Ischemia Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Critical Limb Ischemia Drug Value Chain Analysis
  2. 8.1.1 Critical Limb Ischemia Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Critical Limb Ischemia Drug Production Mode & Process
  5. 8.2 Critical Limb Ischemia Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Critical Limb Ischemia Drug Distributors
  8. 8.2.3 Critical Limb Ischemia Drug Customers
9 Global Critical Limb Ischemia Drug Analyzing Market Dynamics
  1. 9.1 Critical Limb Ischemia Drug Industry Trends
  2. 9.2 Critical Limb Ischemia Drug Industry Drivers
  3. 9.3 Critical Limb Ischemia Drug Industry Opportunities and Challenges
  4. 9.4 Critical Limb Ischemia Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst